Considering that rpS6 is a downstream effector of both the ERK and the mTOR pathways linked to cancer development and metastasis [12,41,42,46], the mTOR-selective inhibitor rapamycin was used to investigate the involvement of the mTOR pathway in the EGF-mediated signalling transduction. This evidence concerns the gene RPS6 and cancer.